Floatz logo

Tuvonralimab

Advanced Colorectal Cancer in the Third-line Treatment and Beyond

JIANG LONGWEIPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

839 Active assets in the Advanced Colorectal Cancer in the Third-line Treatment and Beyond cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

Tuvonralimab is also rated in:

CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →